

Date: October 29, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Outcome of Board Meeting of the Company held on Thursday, October 29, 2026

Dear Sir/Ma'am,

In compliance with Regulations 30, 33, and 47 read with Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Thursday, October 29, 2026, has inter-alia, approved the following:

1. Un-audited Financial Results of the Company

Un-audited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026, together with the Limited Review Report thereon;

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Company hereby confirms and declares that M/s. Pankaj R. Shah and Associates, Chartered Accountants (Firm Registration No. 107361W), Statutory Auditors of the Company have issued their Limited Review Reports on the Un-audited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026.

The financial results along with the reports of the auditors of the Company are enclosed herewith as **Annexure-A**.

Media Release in relation to the Un-audited Consolidated and Standalone financial results of the Company for the quarter and half year ended September 30, 2026, is enclosed herewith as **Annexure -B**.

2. Appointment of Joint Statutory Auditors of the Company

Based on the recommendations of the Audit Committee, the Board of Directors of the Company have approved the appointment M/s Talati and Talati LLP, Chartered Accountants (Firm Registration No. 110758W / W100377), as Joint Statutory Auditors of the Company, along with the existing Statutory Auditors, M/s. Pankaj R Shah & Associates, Chartered Accountants, for the period from 2026-27 to 2030-31.

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure-C**.

Kindly note that the meeting of Board of Directors of the Company commenced at 12:00 Noon (IST) and concluded at 01:30 P.M. (IST).

This intimation and aforesaid information are also being uploaded on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

SHILPA SHARMA
Digitally signed by SHILPA SHARMA
DN: cn=SHILPA SHARMA, c=IN,
o=Personal,
email=csshilpa.agarwal@gmail.com
Date: 2026.10.29 13:51:21 +05'30'

Shilpa Sharma

Company Secretary & Compliance Officer

Membership Number: A34516

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Pankaj R Shah & Associates

Chartered Accountants

CA. DR. Pankaj Shah B.Com., F.C.A., Ph. D. (Commerce)	CA. Chintan Shah B.Com., L.L.B., F.C.A.	CA. Nilesh Shah B.Com., L.L.B., F.C.A.	CA. Manali Shah B.Com., F.C.A.	CA. Sandip Gupta B.Com., F.C.A.
--	--	---	-----------------------------------	------------------------------------

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. URL : <http://www.prsca.in>

Independent Auditors Limited Review Report on Unaudited Consolidated Financial Results of Senores Pharmaceuticals Limited for the quarter and half year ended September 30, 2026 pursuant to the Regulation 33 of Security Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, (the "Listing Regulations").

Review Report to,
The Board of Directors

Senores Pharmaceuticals Limited,

We have reviewed the consolidated statement of unaudited consolidated financial results of **Senores Pharmaceuticals Limited** (the "company") for the quarter and half year ended on September 30, 2026 (the "statement") including its subsidiary's share of net profit/ after tax and total comprehensive income/loss, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

Includes the financial results of following entities:

Parent:

Senores Pharmaceuticals Limited

Subsidiary:

Senores Pharmaceuticals Inc.
Ratnatris Pharmaceuticals Private Limited
Havix Group Inc.
Apnar Pharma Private Limited

Step down Subsidiary:

9488 Jackson Trail LLC
Zoraya Pharmaceuticals LLC
Amerisyn LLC

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of



material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The accompanying statements includes unaudited interim financial results of 4 subsidiaries and 3 Stepdown subsidiaries included in the statement, whose unaudited interim financial results reflect total assets (before consolidation adjustment) of Rs. 1,414.74 Crores as at September 30, 2026, total revenue (before consolidation adjustment) Rs. 375.62 Crores, total Net Profit after tax of Rs. 44.11 Crores and total Comprehensive Income of Rs. 44.11 Crores for the Half-year ended September 30, 2026 and cashflow (net) (before consolidation adjustment) of Rs. (6.81) Crores for the period from April 1, 2026 to September 30, 2026, as considered in the respective consolidated unaudited financial results. These unaudited interim financial results of this subsidiary have been reviewed by their respective auditors and have been approved and furnished to us by the management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such unaudited interim financial results and information. Our conclusion is not modified in respect of this matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

Tax Provisions and Deferred Tax have been determined as estimated by the management solely. Our conclusion on the statement is not modified in the respect of these matters.


Date: 29-10-2026

Place: Ahmedabad

For, Pankaj R Shah & Associates

Chartered Accountants

Registration No.107361W



CA Dhruvik Shah

Partner

Membership No.137738

UDIN: 26137738YXSEAD3581



SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30,2026
(INR in Crores, except EPS)

Sr No.	Particulars	For Quarter ended			Half Year ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	192.33	180.21	153.94	372.54	286.50	632.63
2	Other Income	8.94	2.81	13.23	11.75	22.01	47.06
3	Total Income	201.27	183.02	167.17	384.29	308.51	679.69
4	Expenses						
	Cost of materials consumed	28.39	31.15	46.09	59.54	75.46	114.27
	Purchases of stock-in-trade	37.45	34.01	11.00	71.46	38.55	137.32
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.74	0.56	(0.01)	1.30	4.42	0.07
	Employee benefits expenses	32.41	29.91	29.63	62.32	51.28	112.25
	Finance costs	8.77	7.17	6.19	15.94	11.24	25.03
	Depreciation & Amortisation expenses	10.25	9.94	8.09	20.19	14.09	31.25
	Other expenses	35.68	30.82	25.55	66.50	46.36	100.40
	Total Expenses	153.69	143.56	126.53	297.25	241.40	520.59
5	Profit Before Tax	47.58	39.46	40.64	87.04	67.11	159.10
6	Tax expense						
	Current tax	12.72	9.82	11.36	22.54	16.27	19.94
	Deferred tax	(1.74)	(0.81)	(0.85)	(2.55)	(0.45)	17.63
	Total Tax Expense	10.98	9.01	10.51	19.99	15.82	37.57
7	Net Profit after tax	36.60	30.45	30.12	67.05	51.29	121.53
8	Other Comprehensive Income / (Loss)						
	A (i) Items that will not be reclassified subsequently to profit or loss	0.01	0.00	(0.14)	0.01	(0.14)	(0.02)
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	-	0.04	-	0.04	(0.01)
	B (i) Items that will be reclassified subsequently to profit or loss	3.35	0.51	(8.30)	3.86	(7.83)	29.22
	(ii) Income tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
	Total Other Comprehensive Income / (Loss)	3.36	0.51	(8.40)	3.87	(7.93)	29.19
9	Total Comprehensive Income	39.96	30.96	21.72	70.92	43.36	150.72
10	Profit for the period attributable to Equity Holders of the Company	39.49	30.72	32.38	70.21	52.11	115.38
	Non Controlling Interests	(2.89)	(0.27)	(2.26)	(3.16)	(0.82)	6.16
	Other Comprehensive Income attributable to Equity Holders of the Company	3.77	0.48	(6.66)	4.25	(6.34)	26.96
	Non Controlling Interests	(0.41)	0.03	(1.74)	(0.38)	(1.59)	2.23
	Total Comprehensive Income attributable to Equity Holders of the Company	43.26	31.20	25.72	74.46	45.77	142.34
	Non Controlling Interests	(3.30)	(0.24)	(4.00)	(3.54)	(2.41)	8.39
11	Paid up Equity Share Capital (Face Value Rs 10 per share)						46.05
12	Other Equity						887.55
13	Earnings per share (Face Value Rs 10 per share) (Not annualised for the Quarter and Half year)						
	Basic	8.85	6.61	6.54	15.25	11.14	26.39
	Diluted	8.82	6.60	6.54	15.20	11.14	26.39



For Senores Pharmaceuticals Limited

Swapnil Jatinbhai Shah

Managing Director

DIN: 05259821

Place : Ahmedabad

Date : October 29,2026

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Unaudited Consolidated Balance Sheet as at 30th September, 2026

(INR in Crores)

Particulars		As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
A	ASSETS		
1	Non Current Assets		
	Property, Plant and Equipment	336.18	331.37
	Capital work-in-progress	31.12	17.46
	Goodwill	46.55	46.55
	Other Intangible assets	109.08	106.79
	Intangible Assets under Development	311.14	232.00
	Right of Use Assets	23.69	13.88
	Investment property	24.75	24.60
	Financial Assets		
	Investments	5.94	4.29
	Other Financial Assets	18.90	10.22
	Deferred Tax Assets (net)	2.28	-
	Other Non-Current Assets	4.66	4.22
	Total Non Current Assets	914.29	791.38
2	Current Assets		
	Inventories	97.56	89.29
	Financial Assets		
	Trade Receivable	253.23	324.82
	Cash and cash equivalents	17.96	45.55
	Bank Balance other than above	82.70	114.06
	Other Financial Assets	224.33	172.68
	Other Current Assets	90.53	66.03
	Total Current Assets	766.31	812.43
	TOTAL ASSETS (1+2)	1,680.60	1,603.81
B	EQUITY AND LIABILITIES		
1	Equity		
	Share capital	46.05	46.05
	Other Equity	956.93	887.55
	Equity Attributable to Equity Holders of the Parent	1,002.98	933.60
	Non - Controlling Interests	28.55	30.94
	Total Equity	1,031.53	964.54
2	Liabilities		
	Non Current Liabilities		
	Financial Liabilities		
	Borrowings	212.87	194.89
	Lease Liabilities	19.19	13.18
	Provisions	5.42	6.61
	Deferred tax liabilities (net)	-	0.59
	Total Non Current Liabilities	237.48	215.27
	Current Liabilities		
	Financial Liabilities		
	Borrowings	181.62	132.20
	Lease Liabilities	3.11	1.76
	Trade payables		
	(A) Dues to Micro and Small Enterprises	3.12	11.90
	(B) Dues to Other than Micro and Small Enterprises	147.93	222.82
	Other Financial Liabilities	12.70	17.59
	Other Current Liabilities	22.03	14.79
	Provisions	7.20	2.71
	Current Tax Liabilities (Net)	33.88	20.23
	Total Current Liabilities	411.59	424.00
	TOTAL EQUITY AND LIABILITIES (1+2)	1,680.60	1,603.81

Place : Ahmedabad
Date : October 29, 2026



For Senores Pharmaceuticals Limited

[Signature]
Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Statement of Unaudited Consolidated Cash Flows for the Half year ended 30th September, 2026

(INR in Crores)

Particulars	Half year ended	
	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)
(A) Cash Flow from Operating Activities :		
Profit Before Tax	87.04	67.11
Adjustments for :		
Depreciation & Amortisation expense	20.19	14.09
Interest Income	(3.38)	(8.76)
Finance Cost	15.55	10.86
Interest on Lease Liabilities	0.39	0.38
Effect of Foreign Exchange rate movement	3.40	(8.79)
Operating Profit Before Working Capital Changes	123.19	74.89
Movement in Working Capital		
Adjustments for decrease / (increase) in Assets		
Inventories	(8.27)	(5.98)
Trade Receivables	71.59	(75.77)
Other Financial Assets	(51.60)	(43.07)
Other Non-Current Assets	(0.02)	(6.13)
Other Current Assets	(24.50)	(1.72)
Adjustments for (decrease) / increase in Liabilities		
Trade Payables	(83.65)	56.57
Other Financial Liabilities	1.21	5.45
Other Current Liabilities	7.24	24.97
Provisions	3.30	2.18
Cash Generated from Operations	38.48	31.38
Direct Taxes Paid (Net)	(9.26)	(7.16)
Net Cash generated / (utilised) from Operating Activities (A)	29.22	24.22
(B) Cash Flow from Investing Activities :		
Payments for purchase of Property, Plant and Equipment, Intangible Assets, Capital Work in Progress and Right to use assets	(136.59)	(96.69)
Acquisition of shares in existing Foreign Subsidiaries	-	(18.01)
Proceeds / (investment) in Bank deposits having maturity more than three months	22.68	149.03
Increase in Investments in other shares & securities (Net)	(1.65)	(1.78)
Interest Received	3.38	8.76
Net Cash utilised in Investing Activities (B)	(112.18)	41.31
(C) Cash Flow from Financing Activities:		
Proceeds from /(Repayment of) Non Current Borrowings (Net)	17.98	(9.76)
Proceeds from/(Repayment of) Current Borrowings (Net)	49.43	(63.17)
Payments for Buyback of shares by Foreign Subsidiary	(1.92)	-
Repayment of External Commercial Borrowings (ECB) of Domestic Subsidiary	(3.25)	-
Proceeds from Issue of capital to Non-controlling Interest	1.70	-
Increase /(decrease) in Lease Liabilities	7.36	(0.71)
Interest on Lease Liabilities	(0.39)	(0.38)
Finance Cost paid	(15.55)	(10.86)
Net Cash generated / (utilised) in Financing Activities (C)	55.36	(84.88)
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(27.59)	(19.35)
Cash and Cash Equivalents as at Beginning of the period	45.55	105.38
Cash and Cash Equivalents as at End of the period	17.96	86.03



Place : Ahmedabad
Date : October 29, 2026

For Senores Pharmaceuticals Limited

[Signature]
Swapnil Jatinbhai Shah
Managing Director

DIN: 05259821

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Notes to Consolidated Financial Results:

1. The consolidated unaudited financial results of Senores Pharmaceuticals Limited ("Company") for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meetings held on October 29, 2026. The Statutory auditors have carried out a limited review of the consolidated financial results of the Company for the quarter and half year ended September 30, 2026.
2. The consolidated unaudited financial results of Senores Pharmaceuticals Limited have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
3. The consolidated unaudited financial results include the results of the following subsidiaries and step-down subsidiaries:
 - i. Senores Pharmaceuticals Inc
 - ii. Havix Group Inc
 - iii. Ratnatris Pharmaceuticals Private Limited
 - iv. Apnar Pharma Private Limited
 - v. 9488 Jackson Trail LLC (Step-Down Subsidiary)
 - vi. Zoraya Pharmaceuticals LLC (Step-Down Subsidiary)
 - vii. Amerisyn, LLC (Step-Down Subsidiary)
4. The Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.
5. During the previous year, the Company had acquired 75% equity stake in Apnar Pharma Private Limited ("Apnar") on 16th January, 2026 in accordance with the Share Purchase Agreement ("SPA") with its selling Shareholders. As per the SPA, the balance 25% equity stake in Apnar will be acquired post completion of due certain formalities as mentioned in the SPA. The consideration payable to the remaining selling shareholders is disclosed under the Financial Liabilities. The Company has made line by line consolidation of items of profit and loss and Balance sheet after Acquisition and has given effect of Goodwill arising out of this Acquisition as per IND AS 103 while preparing these consolidated unaudited financial results.
6. The Board of Directors, at its meeting held on March 28, 2026, allotted 11,70,000 warrants to the Promoter and Promoter Group on a preferential basis, aggregating ₹95 crore at an issue price of ₹812 per warrant, pursuant to the shareholders' approval received on January 31, 2026. Each warrant is convertible into one equity share within 18 months from the date of allotment. During the year ended March 31, 2026, the Company received ₹23.75 crore, representing the minimum upfront subscription amount of 25% of the issue price.



SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

7. The Proceeds of IPO have been utilized till September 30, 2026 as per the below mentioned table:

(Rs in crores)

Sr. No	Item Head	Amount as proposed in the Offer Document and as Revised as on September 30, 2026	Amount utilized till September 30, 2026	Amount unutilized as on September 30, 2026	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility (Refer Note 1)	41.98	6.98	35.00	Out of the unutilized amount, Rs 81.11 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.06 crores held in HDFC bank account
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company (Refer Note 3 below)	73.10	73.10	0.00	
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00	
4	Funding the working capital requirements of our Company	43.26	43.26	0.00	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes (Refer Notes 2 & 3 below)	161.91	161.91	0.00	
7	Offer expenses (Refer Note 3)	35.04	34.99	0.05	
8	Investment in subsidiary SPI to fund the acquisition of ANDAs. (Refer Note 1)	15.39	10.07	5.32	
9	Investment in one of the subsidiaries, Apnar, to fund the capital expenditure requirements for expansion of its existing manufacturing facility in Vadodara. (Refer Note 1)	25.00	1.69	23.32	
10	Investment in one of the subsidiaries, Havix, to fund the capital expenditure requirements for expansion of the existing OSD manufacturing facility in Atlanta. (Refer Note 1)	24.63	7.14	17.48	
	Total	500.00	418.83	81.17	

Note 1: The Company had sought shareholder approval for variation in the objects / terms of utilization of IPO proceeds and extension of time limit through postal ballot, which got approved by e-voting by the members as mentioned in the scrutinizer report dated August 04, 2026, and accordingly the objects and its timelines have been revised.

Note 2: The utilization of Rs. 0.28 crores is under the head of GCP towards capex in SPL under the head expansion initiatives. On aggregate basis upto Q2FY27, the company has utilised total Rs. 161.91 crore out of which Rs. 70.09 crore is towards GCP and remaining Rs. 91.82 crore is towards other strategic initiatives.



SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Note 3:

- i. Surplus portion of Rs. 0.38 crores on fulfillment of Object-2 & Rs. 0.02 crores on fulfillment of Object-3 are transferred to Object-6 (General Corporate Purpose ("GCP")) as approved by the Board in its meeting dated July 23, 2025.
 - ii. Surplus portion of Rs. 6.31 crores of Object 7 have been transferred to Object 6 (General Corporate Purpose ("GCP")) as approved by the Board in its meeting dated March 28, 2026.
 - iii. Out of the surplus portion of Offer Expenses Rs.0.84 crore is transferred to the object of Funding inorganic growth through acquisition and other strategic initiatives and General Corporate Purpose (GCP) as approved in the board meeting dated May 14,2026.
8. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
9. The Group is operating in a single segment i.e. Pharmaceuticals. Hence, the above financial results are based on a single segment only.
10. Previous period figures have been regrouped and / or re-arranged wherever necessary to make their classification comparable with current period.

Place: Ahmedabad

Date: October 29, 2026



For Senores Pharmaceuticals Limited

A handwritten signature in black ink, appearing to read "Swapnil Jatinbhai Shah".

Swapnil Jatinbhai Shah

Managing Director

DIN: 05259821

Pankaj R Shah & Associates

Chartered Accountants

CA. DR. Pankaj Shah
B.Com., F.C.A., Ph. D. (Commerce)

CA. Chintan Shah
B.Com., L.L.B., F.C.A.

CA. Nilesh Shah
B.Com., L.L.B., F.C.A.

CA. Manali Shah
B.Com., F.C.A.

CA. Sandip Gupta
B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. URL : <http://www.prsca.in>

Independent Auditors Limited Review Report on Unaudited standalone financial results of Senores Pharmaceuticals Limited for the quarter and half year ended September 30, 2026 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to

The Board of Directors

Senores Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited Standalone Ind AS Financial Results of Senores Pharmaceuticals Limited (the "Company"), for the quarter and half year ended September 30, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not



disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

Tax Provisions and Deferred Tax have been determined as estimated by the management solely. Our conclusion on the statement is not modified in the respect of these matters.

For Pankaj R Shah & Associates
Chartered Accountants
(Firm Regn.No.107361W)

D.B. Shah

CA Dhrutik Shah

Partner

Membership No. 107414

UDIN : 26137738PKQEMX7312

Place: Ahmedabad

Date: 29-10-2026



Senores Pharmaceuticals Limited

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended September 30, 2026

(INR in Crores, except EPS)

Sr No.	Particulars	For Quarter ended			For Half Year Ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	35.65	26.99	28.01	62.64	44.14	106.09
2	Other Income	14.76	9.55	18.68	24.31	30.76	66.35
3	Total Income	50.41	36.54	46.69	86.95	74.90	172.44
4	Expenses						
	Cost of materials consumed	8.16	7.47	1.00	15.63	2.39	24.55
	Purchases of stock-in-trade	4.69	4.19	11.00	8.88	13.34	30.42
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.05)	0.49	(0.37)	0.44	3.04	(0.30)
	Employee benefits expenses	12.08	10.10	11.59	22.18	18.50	38.78
	Finance costs	2.22	2.22	1.58	4.44	3.34	6.98
	Depreciation & Amortisation expenses	3.93	3.61	3.65	7.54	5.52	13.23
	Other expenses	9.71	7.07	10.59	16.78	17.51	31.32
	Total Expenses	40.74	35.15	39.03	75.89	63.64	144.98
5	Profit Before Tax	9.67	1.39	7.65	11.06	11.26	27.46
6	Tax expense						
	Current tax	2.01	0.31	1.02	2.32	1.41	8.45
	Deferred tax	(0.06)	0.05	0.21	(0.01)	0.72	(1.24)
	Total Tax Expense	1.95	0.36	1.23	2.31	2.13	7.21
7	Profit for the year (5-6)	7.72	1.03	6.43	8.75	9.13	20.25
8	Other Comprehensive Income / (Loss)						
	A (i) Items that will be reclassified to profit or loss	0.00	0.00	(0.14)	0.01	(0.14)	(0.01)
	(ii) Income tax relating to items that will be reclassified to profit and loss	(0.00)	(0.00)	0.04	(0.00)	0.04	0.00
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	-	-	-	-	-
	Total Other Comprehensive Income / (Loss)	0.00	0.00	(0.10)	0.00	(0.10)	(0.01)
9	Total Comprehensive Income	7.72	1.03	6.33	8.75	9.03	20.24
10	Paid up Equity Share Capital (Face Value Rs 10 per share)						46.05
11	Other Equity						703.85
12	Earnings per share (Face Value Rs 10 per share) (Not annualised for quarter and half year)						
	Basic	1.68	0.22	1.40	1.90	1.98	4.40
	Diluted	1.67	0.22	1.40	1.89	1.98	4.40

Place : Ahmedabad
Date: October 29, 2026



For Senores Pharmaceuticals Limited

(Signature)
Swapnil Jalimbhai Shah
Managing Director
DIN: 05259821

Senores Pharmaceuticals Limited

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Unaudited Standalone Balance Sheet as at 30th September, 2026

		(INR in Crores)	
Particulars		As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
A	ASSETS		
1	Non Current Assets		
	Property, Plant and Equipment	89.82	84.87
	Capital Work-in-Progress	6.35	8.54
	Intangible Asset Under Development	4.73	3.76
	Other Intangible Assets	-	0.01
	Right of Use Assets	19.51	13.04
	Financial Assets		
	Investments	154.62	154.48
	Loan	422.86	360.98
	Other Financial Assets	14.34	3.70
	Deferred Tax Assets (net)	1.55	1.54
	Other Non-Current Assets	1.13	1.34
	Total Non Current Assets	714.91	632.27
2	Current assets		
	Inventories	9.89	9.75
	Financial Assets		
	Trade Receivable	66.69	76.46
	Cash and Cash equivalents	11.31	32.22
	Bank Balance other than above	82.38	113.79
	Other Financial Assets	3.73	-
	Other Current Assets	29.22	23.42
	Total Current Assets	203.22	255.64
	TOTAL ASSETS	918.13	887.91
B	EQUITY AND LIABILITIES		
1	Equity		
	Share capital	46.05	46.05
	Other Equity	712.61	703.85
	Total Equity	758.66	749.90
2	Liabilities		
	Non Current Liabilities		
	Financial Liabilities		
	Borrowings	55.72	51.77
	Lease Liabilities	18.07	12.04
	Provisions	3.49	4.64
	Deferred tax liabilities (net)	-	-
	Total Non Current Liabilities	77.28	68.45
	Current Liabilities		
	Financial Liabilities		
	Borrowings	33.82	19.74
	Lease Liabilities	2.53	1.83
	Trade payables		
	(A) Dues of Micro Enterprises and Small Enterprises	3.12	2.18
	(B) Dues of creditors other than Micro Enterprises and small Enterprise	25.98	29.25
	Other Financial Liabilities	5.72	10.02
	Other Current Liabilities	1.32	1.41
	Provisions	3.72	0.50
	Current Tax Liabilities (Net)	5.98	4.64
	Total Current Liabilities	82.19	69.57
	TOTAL EQUITY AND LIABILITIES	918.13	887.91

Place : Ahmedabad
Date: October 29, 2026



For Senores Pharmaceuticals Limited

Swapnil Jainbhai Shah
Swapnil Jainbhai Shah
Managing Director
DIN: 05259821

Senores Pharmaceuticals Limited

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Statement of Unaudited Standalone Cash Flows for the Half Year ended September 30, 2026

(INR in Crores)

Particulars	For Half Year ended	
	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)
(A) Cash Flow from Operating Activities :		
Profit Before Tax	11.06	11.26
Adjustments for :		
Depreciation & Amortisation expenses	7.54	5.52
Interest Income	(19.29)	(19.75)
Interest on Lease Liabilities	0.34	-
Finance Cost	4.10	3.34
Effect of Foreign Exchange rate movement	(0.36)	(6.67)
Remeasurement of Defined Benefit	-	(0.14)
Operating Profit Before Working Capital Changes	3.39	(13.12)
Movement in Working Capital		
Adjustments for decrease / (increase) in Assets		
Inventories	(0.14)	0.84
Trade Receivables	9.77	(20.06)
Other Financial Assets	(3.67)	0.40
Other Non-Current Assets	0.00	0.27
Other Current Assets	(5.80)	(1.85)
Adjustments for (decrease) / increase in Liabilities		
Trade Payables	(2.33)	3.37
Other Financial Liabilities	0.90	6.25
Other Current Liabilities	(0.09)	0.76
Provisions	2.07	1.80
Cash Generated from Operations	4.11	(21.35)
Direct Taxes Paid (Net)	(0.97)	-
Net Cash generated / (used) from Operating Activities (A)	3.14	(21.35)
(B) Cash Flow from Investing Activities		
Payments for purchase of Property, Plant and Equipment, Intangible Assets, Capital Work in Progress and Right to use assets	(22.71)	(14.30)
Acquisition of Shares in Subsidiaries	-	(36.94)
Decrease/ (Increase) in Loans to Subsidiaries	(61.51)	(62.93)
Proceeds / (investment) in Bank deposits having maturity more than three months	20.71	-
Investments in Mutual Funds/Shares & Securities	(0.14)	147.88
Interest Received	19.29	19.75
Net Cash generated / (used) form Investing Activities (B)	(44.36)	53.45
(C) Cash Flow from Financing Activities:		
Proceeds from /(Repayment of) Non Current Borrowings (Net)	3.95	(41.21)
Proceeds from/(Repayment of) Current Borrowing (Net)	14.08	5.86
Increase/Decrease in Lease liabilities	6.73	1.43
Interest on Lease Liabilities	(0.34)	-
Finance Cost Paid	(4.10)	(3.34)
Net Cash generated / (used) in Financing Activities (C)	20.31	(30.58)
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(20.91)	1.52
Cash and Cash Equivalents as at Beginning of the Period	32.22	81.20
Cash and Cash Equivalents as at End of the period	11.31	82.72



Place : Ahmedabad
Date: October 29, 2026

For Senores Pharmaceuticals Limited

Swapnil
Swapnil Jatinbhai
Managing Director
DIN: 05259821

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Notes to Standalone Financial Results:

1. The Standalone unaudited financial results of Senores Pharmaceuticals Limited ("Company") for the quarter ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meetings held on October 29, 2026. The Statutory auditors have carried out a limited review of the Standalone financial results of the Company for the quarter ended September 30, 2026.
2. The standalone unaudited financial results of Senores Pharmaceuticals Limited have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
3. The Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.
4. The Proceeds of IPO have been utilized till September 30, 2026 as per the below mentioned table:

Sr. No	Item Head	Amount as proposed in the Offer Document and as Revised as on September 30, 2026	Amount utilized till September 30, 2026	Amount unutilized as on September 30, 2026	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility. (Refer Note 1)	41.98	6.98	35.00	Out of the unutilized amount, Rs 81.11 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.06 crores held in HDFC bank account
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company (Refer Note 3 below)	73.10	73.10	0.00	
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00	
4	Funding the working capital requirements of our Company	43.26	43.26	0.00	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes (Refer Notes 2 & 3 below)	161.91	161.91	0.00	
7	Offer expenses (Refer Note 3)	35.04	34.99	0.05	
8	Investment in subsidiary SPI to fund the acquisition of ANDAs. (Refer Note 1)	15.40	10.08	5.32	
9	Investment in one of the subsidiaries, Apnar, to fund the capital expenditure requirements for expansion of its existing manufacturing facility in Vadodara. (Refer Note 1)	25.00	1.69	23.32	
10	Investment in one of the subsidiaries, Havix, to fund the capital expenditure requirements for expansion of the existing OSD manufacturing facility in Atlanta. (Refer Note 1)	24.63	7.14	17.48	
	Total	500.00	418.83	81.17	



SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Note 1: The Company had sought shareholder approval for variation in the objects / terms of utilization of IPO proceeds and extension of time limit through postal ballot, which got approved by e-voting by the members as mentioned in the scrutinizer report dated August 04, 2026, and accordingly the objects and its timelines have been revised. ,

Note 2: The utilization of Rs. 0.28 crores is under the head of GCP towards capex in SPL under the head expansion initiatives. On aggregate basis upto Q2FY27, the company has utilised total Rs. 161.91 crore out of which Rs. 70.09 crore is towards GCP and remaining Rs. 91.82 crore is towards other strategic initiatives.

Note 3:

- i. Surplus portion of Rs. 0.38 crores on fulfillment of Object-2 & Rs. 0.02 crores on fulfillment of Object-3 are transferred to Object-6 (General Corporate Purpose ("GCP")) as approved by the Board in its meeting dated July 23, 2025.
 - ii. Surplus portion of Rs. 6.31 crores of Object 7 have been transferred to Object 6 (General Corporate Purpose ("GCP")) as approved by the Board in its meeting dated March 28, 2026.
 - iii. Out of the surplus portion of Offer Expenses Rs.0.84 crore is transferred to the object of Funding inorganic growth through acquisition and other strategic initiatives and General Corporate Purpose (GCP) as approved in the board meeting dated May 14,2026.
5. The Board of Directors, at its meeting held on March 28, 2026, allotted 11,70,000 warrants to the Promoter and Promoter Group on a preferential basis, aggregating ₹95 crore at an issue price of ₹812 per warrant, pursuant to the shareholders' approval received on January 31, 2026. Each warrant is convertible into one equity share within 18 months from the date of allotment. During the year ended March 31, 2026, the Company received ₹23.75 crore, representing the minimum upfront subscription amount of 25% of the issue price.
 6. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
 7. The Company operates in a single segment i.e. Pharmaceuticals. Hence, the above financial results are based on a single segment only.
 8. Previous period figures have been regrouped and/or rearranged, wherever necessary to make their classification comparable with current period.

Place: Ahmedabad

Date: October 29, 2026



For Senores Pharmaceuticals Limited

Swapnil Jatinbhai Shah

Managing Director

DIN: 05259821

SENORES PHARMACEUTICALS LIMITED

Robust Financial & Operational Performance in Q2 and H1 FY27 Highest-ever quarterly Revenue and EBITDA in Q2FY27

Ahmedabad, Gujarat, 29th October 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its unaudited Financial Result for the quarter and half year ended 30th September 2026.

Q2 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS

Revenue ₹ 192 crs  +25% Y-o-Y	EBITDA ₹ 58 crs  +38% Y-o-Y	PAT ₹ 37 crs  +22% Y-o-Y
---	---	--

H1 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS

Revenue ₹ 373 crs  +30% Y-o-Y	EBITDA ₹ 111 crs  +58% Y-o-Y	PAT ₹ 67 crs  +31% Y-o-Y
---	--	--

Q2 & H1 FY27 SEGMENTAL HIGHLIGHTS

Segment Revenue (₹ crs)	Q2FY27	Q2FY26	Y-o-Y	H1FY27	H1FY26	Y-o-Y
Regulated Markets	136.7	106.9	27.9%	264.5	196.9	34.3%
Emerging Markets	38.4	31.7	21.2%	76.0	60.7	25.3%
Branded Generics	9.5	11.9	-20.5%	17.5	20.2	-13.4%
Others	7.8	3.4	126.2%	14.6	8.7	67.2%
Total Revenue	192.3	153.9	24.9%	372.5	286.5	30.0%

Q2 and H1 FY27 PERFORMANCE HIGHLIGHTS

✓ **Consistently strong and broad-based growth across businesses**

- Consistently delivering robust performance. Revenue for Q2 and H1 FY27 growing by **25% and 30% Y-o-Y respectively**.
- Regulated & Emerging Market revenues grew by **34% & 25% respectively** on a Y-o-Y basis in H1.

✓ **Robust improvement in profitability**

- EBIDTA for Q2 and H1 FY27 grew by 38% and 58% with margin expansion of ~290 bps and ~530 bps on a Y-o-Y basis respectively.
- EBITDA could have been even higher but for initial set-up and operating costs associated with Zoraya and Amerisyn, without corresponding revenue generation.

✓ **Continued expansion of product portfolio**

- Nearly doubled our Regulated Markets portfolio, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, out of which 23 ANDAs have been commercialized.

✓ **Improvement in cash flow generation**

- Cash from Operations stood at ₹ 38 crores in H1FY27, consistent improvement in cash flow generation trajectory over the last 12-18 months.

✓ **Emerging Markets on Steady Trajectory**

- Emerging Markets business on a steady growth trajectory. Revenue growing by 21% and 25% Y-o-Y in Q2 and H1 FY27 respectively. Increasing focus on niche products and streamlined go-to-market strategies.

✓ **Outlook remains positive**

- On track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. This is underpinned by a robust product pipeline, with strong visibility of commercial launches over the course of the year.

Commenting on the performance, **Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“We delivered another robust performance in Q2 and H1 FY27, marking our 9th consecutive quarter of healthy double-digit growth. Strong execution, operational excellence and diversified business operations continue to drive growth and strengthen our business fundamentals.

Our Regulated Markets business sustained strong momentum, with our ANDA portfolio nearly doubling to 64, including 23 commercialized products and 41 planned launches over the next 18–24 months. Strong launch readiness, the scaling up of our Apnar facility, and the upcoming contributions from Zoraya and Amerisyn provide clear growth visibility. Our CDMO/CMO opportunities and pipeline of 41 molecules covering approximately 130 strengths further strengthen our growth platform.

Our Emerging Markets business continued to grow, with improving profitability and positive cash flows. Entry into Europe and the anticipated PIC/S approval for our Chhatral facility are expected to expand market access and support future growth. In India, investments in field-force expansion and market reach position our critical care injectables business for steady progress.

Operating cash flow improved to ₹38 crore in H1 FY27, compared with ₹31 crore in the previous year. While initial costs for Zoraya and Amerisyn temporarily impacted profitability, their anticipated scale-up from FY28 onwards is expected to drive operating leverage and improve margins.

Backed by a robust product pipeline, expanded manufacturing capabilities and strong commercial launch visibility, we remain on track to deliver 30–40% revenue growth and 50–60% PAT growth in FY27, followed by anticipated annual growth of 20–25% over the next two years.”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 64 ANDAs and 19 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 558 product registrations and 944 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant, second in Gujarat, which is also US-FDA approved and the third in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to Emerging Markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact

**Company : SENORES PHARMACEUTICALS LIMITED**

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

**Investor Relations : Strategic Growth Advisors**

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899

Annexure-C

Details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026

Sr. No	Particulars	Details
1.	Name of the Joint Statutory Auditor	M/s Talati and Talati LLP
2.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment
3.	Date of appointment/ ~~re-appointment/~~ ~~cessation (as applicable)~~ & term of appointment ~~/re-appointment~~	October 29, 2026 M/s Talati and Talati LLP, Chartered Accountants (Firm Registration No. 110758W / W100377) has been appointed as the Joint Statutory Auditors of the Company to conduct the Statutory Audit of the Company for the financial year commencing from 2026-27 to 2030-31 subject to shareholders approval.
4.	Brief Profile	M/s. Talati & Talati LLP is a reputed firm of Chartered Accountants registered with the Institute of Chartered Accountants of India ("ICAI"), with over 50 years of professional experience and a presence across 8 cities in India. The Firm has established professional expertise in providing audit and assurance services to clients across various industries, including the manufacturing sector. With its extensive experience and professional capabilities, the Firm possesses the requisite knowledge, competence and expertise to discharge its responsibilities as Statutory Auditors of the Company. Further, the Firm has undergone the peer review process conducted by ICAI and holds a Peer Review Certificate, demonstrating its compliance with the applicable professional peer review requirements.
5.	Disclosure of relationships between Directors	Not Applicable

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263